Provided by Tiger Fintech (Singapore) Pte. Ltd.

ABVC BioPharma, Inc.

2.75
+0.350014.58%
Post-market: 2.800.0500+1.82%19:32 EDT
Volume:320.00K
Turnover:845.76K
Market Cap:44.69M
PE:-12.27
High:2.77
Open:2.39
Low:2.39
Close:2.40
Loading ...
Mar 30, 2024

Correspondence

Form CORRESP - Correspondence
Mar 26, 2024

Major Issues Report

Form 8-K - Current report
Mar 22, 2024

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Mar 15, 2024

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Mar 14, 2024

Major Issues Report

Form 8-K - Current report
Mar 14, 2024

Major Issues Report

Form 8-K - Current report
Mar 13, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 29, 2024

Major Issues Report

Form 8-K/A - Current report: [Amend]
Feb 29, 2024

Major Issues Report

Form 8-K/A - Current report: [Amend]
Feb 17, 2024

Correspondence

Form CORRESP - Correspondence
Feb 16, 2024

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Feb 13, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 10, 2024

Correspondence

Form CORRESP - Correspondence
Feb 09, 2024

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Feb 08, 2024

Major Issues Report

Form 8-K - Current report
Jan 26, 2024

Major Issues Report

Form 8-K/A - Current report: [Amend]
Jan 17, 2024

Major Issues Report

Form 8-K - Current report
Jan 17, 2024

Major Issues Report

Form 8-K - Current report
Jan 17, 2024

Major Issues Report

Form 8-K/A - Current report: [Amend]
Jan 12, 2024

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933